These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 27486987)

  • 41. MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients.
    ElNahass YH; Mahmoud HK; Mattar MM; Fahmy OA; Samra MA; Abdelfattah RM; ElRefaey FA; Fahmy HM; Fathy GM; Abdulgawad A; AbdelKader M; Elleithy HN; Gamil M; Talaat M; Nader HA; ElMetnawy WH
    Leuk Lymphoma; 2018 Apr; 59(4):844-854. PubMed ID: 28828906
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation.
    Haunstrup LM; Ebbesen LH; Hansen M; Severinsen MT; Aggerholm A
    Exp Hematol; 2018 Dec; 68():62-65. PubMed ID: 30292681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation.
    Gau JP; Chen CC; Chou YS; Liu CJ; Yu YB; Hsiao LT; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH
    Blood Cells Mol Dis; 2015 Jun; 55(1):36-9. PubMed ID: 25976465
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
    Elala YC; Lasho TL; Gangat N; Finke C; Barraco D; Haider M; Abou Hussein AK; Hanson CA; Ketterling RP; Pardanani A; Tefferi A
    Am J Hematol; 2016 May; 91(5):503-6. PubMed ID: 26890983
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
    Andrikovics H; Krahling T; Balassa K; Halm G; Bors A; Koszarska M; Batai A; Dolgos J; Csomor J; Egyed M; Sipos A; Remenyi P; Tordai A; Masszi T
    Haematologica; 2014 Jul; 99(7):1184-90. PubMed ID: 24895336
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
    Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
    Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High resolution melting analysis: a rapid and accurate method to detect CALR mutations.
    Bilbao-Sieyro C; Santana G; Moreno M; Torres L; Santana-Lopez G; Rodriguez-Medina C; Perera M; Bellosillo B; de la Iglesia S; Molero T; Gomez-Casares MT
    PLoS One; 2014; 9(7):e103511. PubMed ID: 25068507
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2
    Saki N; Shirzad R; Rahim F; Saki Malehi A
    Clin Transl Oncol; 2017 Jul; 19(7):874-883. PubMed ID: 28205126
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.
    Mózes R; Gángó A; Sulák A; Vida L; Reiniger L; Timár B; Krenács T; Alizadeh H; Masszi T; Gaál-Weisinger J; Demeter J; Csomor J; Matolcsy A; Kajtár B; Bödör C
    Pathology; 2019 Apr; 51(3):301-307. PubMed ID: 30606612
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.
    Palandri F; Latagliata R; Polverelli N; Tieghi A; Crugnola M; Martino B; Perricone M; Breccia M; Ottaviani E; Testoni N; Merli F; Aversa F; Alimena G; Cavo M; Martinelli G; Catani L; Baccarani M; Vianelli N
    Leukemia; 2015 Jun; 29(6):1344-9. PubMed ID: 25801912
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms.
    Wiriyaukaradecha K; Nimsanor S; Tantirukdham N; Tongsom J; Bunyoo C; Soonklang K; Sritana N; Auewarakul C
    Asian Pac J Cancer Prev; 2022 May; 23(5):1671-1678. PubMed ID: 35633552
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.
    Rotunno G; Mannarelli C; Guglielmelli P; Pacilli A; Pancrazzi A; Pieri L; Fanelli T; Bosi A; Vannucchi AM;
    Blood; 2014 Mar; 123(10):1552-5. PubMed ID: 24371211
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Calreticulin mutation burden--is it a stable clone in patients with essential thrombocythemia and myelofibrosis?
    Shuly Y; Nagar M; Ben-Asaf L; Kneller A; Steinberg DM; Amariglio N; Salomon O
    Blood Cells Mol Dis; 2015 Dec; 55(4):281-3. PubMed ID: 26460248
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
    Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
    Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.
    Usseglio F; Beaufils N; Calleja A; Raynaud S; Gabert J
    J Mol Diagn; 2017 Jan; 19(1):92-98. PubMed ID: 27855276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients.
    Zaidi U; Sufaida G; Rashid M; Kaleem B; Maqsood S; Mukry SN; Khan RZA; Munzir S; Borhany M; Shamsi TS
    BMC Cancer; 2020 Mar; 20(1):205. PubMed ID: 32164591
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
    Belcic Mikic T; Pajic T; Sever M
    Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
    Alshemmari SH; Rajan R; Ameen R; Almazyad M
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):483-488. PubMed ID: 33858806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
    Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
    Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in
    Pan Y; Wang X; Wen S; Liu X; Yang L; Luo J
    Hematology; 2022 Dec; 27(1):902-908. PubMed ID: 36000955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.